Merck & Co. (MRK) stock price is up over 19% over the past year. Mizuho's Mara Goldstein says that they maintain a buy rating on the MRK stock with a $100 price target. She states that the key takeaway from the cardiovascular event is potential revenue diversification drivers. Goldstein states that a $10B in peak revenue from the cardiovascular pipeline in the mid-2030s would be a strong offset. Also, the SPDR Biotech ETF (XBI) is down 21% year-to-date.
11 Apr 2022
Morning Trade Live
23 Mar 2022
Morning Trade Live
04 Apr 2022
Market On Close
06 Apr 2022
Market On Close
30 Mar 2022
The Watch List
12 May 2022
Market On Close
05 Apr 2022